UPDATE: Deutsche Bank Reiterates on Aegerion Pharmaceuticals Following Company Analyst Day

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals AEGR, and raised the price target from $107.00 to $115.00. In the report, Deutsche Bank noted, “Following the Aegerion analyst day and our recent channel checks we are increasing our 2014 sales estimates and raising our TP. The following have given us more confidence. Given more docs are prescribing and scripts from current docs are increasing, we expect sales to continue to accelerate. We are adjusting our previous ‘flat' patient adds in 2014 to incremental qoq growth.” Aegerion Pharmaceuticals closed on Tuesday at $80.93.